Cochrane · systematic review · CD005342

Adjuvant platinum‐based chemotherapy for early stage cervical cancer

Falcetta, FS, Medeiros, LRF, Edelweiss, MI, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library

Gynaecological, Neuro-oncology and Orphan Cancer3 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

4

current version

GRADE rated

4

No studies

0

Included studies

NR

No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Summary of findings

Population: patients with early stage cervical cancer

CD005342.PUB4 (current) · 3 questions

Outcome	Effect	Evidence	Status / GRADE
Death from all causes	HR 0.56 [0.36, 0.87]	2 studies · 297 participants	Moderate
Disease progression	HR 0.47 [0.3, 0.74]	2 studies · 297 participants	Moderate
Grade 4 toxicity3	RR 6.26 [2.5, 15.67]	3 studies · 321 participants	Moderate

Summary of findings

Population: patients with early stage cervical cancer

CD005342.PUB4 (current) · 1 question

Outcome	Effect	Evidence	Status / GRADE
Disease progression	HR 1.34 [0.24, 7.66]	1 study · 71 participants	Low Downgraded: imprecision

Comparison

Population: patients with early stage cervical cancer

CD005342.PUB3 · 3 questions

Outcome	Effect	Evidence	Status / GRADE
Death from all causes	HR 0.56 [0.36, 0.87]	2 studies · 243 participants	Moderate
Disease progression	HR 0.47 [0.3, 0.74]	2 studies · 243 participants	Moderate
Grade 4 toxicity	RR 5.66 [2.14, 14.98]	2 studies · 288 participants	Moderate

Comparison

Population: patients with early stage cervical cancer

CD005342.PUB3 · 1 question

Outcome	Effect	Evidence	Status / GRADE
Disease progression	HR 1.34 [0.24, 7.66]	1 study · 71 participants	Low Downgraded: imprecision

Comparison

Population: patients with early stage cervical cancer

CD005342.PUB2 · 3 questions

Outcome	Effect	Evidence	Status / GRADE
Death from all causes	HR 0.56 [0.36, 0.87]	2 studies · 243 participants	Moderate
Disease progression	HR 0.47 [0.3, 0.74]	2 studies · 243 participants	Moderate
Grade 4 toxicity	RR 5.66 [2.14, 14.98]	2 studies · 288 participants	Moderate

Comparison

Population: patients with early stage cervical cancer

CD005342.PUB2 · 1 question

Outcome	Effect	Evidence	Status / GRADE
Disease progression	HR 1.34 [0.24, 7.66]	1 study · 71 participants	Low Downgraded: imprecision